✦ LIBER ✦

46 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - clinical efficacy and immunological results of a phase I study

✍ Scribed by M.R. Weihrauch; M.S. von Bergwelt-Baildon; U. Hacker; H. Richly; U. Holtick; M. Tschaika; M. Schmidt; B. Wittig; B. Nokay; M.E. Scheulen

Book ID: 119602729
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 62 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)71751-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

47 Immunotherapy with the toll-like rece

47 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - safety results of a clinical phase I study

✍ M.R. Weihrauch; H. Richly; M.S. von Bergwelt-Baildon; U. Hacker; A. Shimabukuro- 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

9148 Phase 1 study of the toll-like rece

9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

✍ Smith, D.A.; Conkling, P.; Richards, D.; Alemany, C.; Boyd, T.; Garbo, L.; Wu, H 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Phase I Active Immunotherapy With Combin

Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors

✍ Kaumaya, P. T.P.; Foy, K. C.; Garrett, J.; Rawale, S. V.; Vicari, D.; Thurmond, 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 217 KB

552 Evaluation of the pharmacokinetic (P

552 Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a phase I study

✍ C. Delbaldo; J.Y. Pierga; V. Dieras; S. Faivre; M. Bonnay; J.C. Vedovato; M. Mue 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Phase I Pharmacokinetic and Pharmacodyna

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

✍ Paz-Ares, L. G.; Gomez-Roca, C.; Delord, J.-P.; Cervantes, A.; Markman, B.; Corr 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 192 KB

411 POSTER A phase I, open-label, dose-e

411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

✍ R. Salgia; A. Peterson; S. Eppler; W. Yu; B. Polite; D. Geary; E. Wesolowski; M. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB